MODERNA, INC. DAVOS - MODERNA CEO SAYS HE WANTS TO HAVE MRNA FACTORY ON EVERY CONTINENT
Davos - Moderna Ceo Says He Wants To Have Mrna Factory On Every…
January 18, 2023 at 03:15 am
Share
Share
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 124.1 USD | -0.87% |
|
+5.63% | +24.74% |
| 07-17 | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
| 07-15 | Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing | MT |
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2024-08-01
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
124.1
USD
Average target price
145.9
USD
Spread / Average Target
+17.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.74% | 47.96B | |
| -0.47% | 42.45B | |
| +43.96% | 41.47B | |
| +25.40% | 31.6B | |
| +17.96% | 28.63B | |
| -4.47% | 28.03B | |
| +50.73% | 14.56B | |
| +42.56% | 14.14B | |
| +1.46% | 12.58B | |
| -5.60% | 11.71B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Davos - Moderna Ceo Says He Wants To Have Mrna Factory On Every…